Opthea ISIN: US68386J2087 Branche: Gesundheit, Biotechnologie
Kursdetails
| Geld (bid) | 3,40 (1.000) |
|---|---|
| Brief (ask/offer) | 3,50 (3.400) |
| Spread | 2,86 |
| Geh. Stück | 1.757 |
| Eröffnung | 3,50 |
| Vortag | 3,64 |
| Tageshoch | 3,50 |
| Tagestief | 3,44 |
| 52W Hoch | 4,76 |
| 52W Tief | 1,60 |
Tagesvolumen
| in USD gehandelt | 4.849 Stk |
|---|---|
| in EUR gehandelt | 0 Stk |
| Gesamt | 4.849 Stk |
Partner-News
Anzeige18:01 Uhr • Partner • Societe Generale
16:45 Uhr • Partner • Societe Generale
16:07 Uhr • Partner • Societe Generale
15:24 Uhr • Partner • Societe Generale
15:20 Uhr • Partner • onemarkets Blog
Aktien-News
22:15 Uhr • Artikel • dpa-AFX
19:43 Uhr • Artikel • BörsenNEWS.de
19:34 Uhr • Artikel • BörsenNEWS.de
19:31 Uhr • Partner • shareribs
Geld/Brief Kurse
Neu laden| Börse | Geld | Vol. | Brief | Vol. | Zeit | Vol. ges. | Kurs |
|---|---|---|---|---|---|---|---|
| NYS | 3,16 | 200 Stk | 3,75 | 200 Stk | 1714089600 02:00 | 3,63 USD | |
| AMEX | 1710201600 12. Mar | 193 Stk | 3,39 USD | ||||
| UTP Consolidated | 3,40 | 1.000 Stk | 3,50 | 3.400 Stk | 1714161600 22:00 | 2.899 Stk | 3,49 USD |
| Baader Bank | 3,16 | 155 Stk | 3,28 | 157 Stk | 1714157648 20:54 | 3,22 EUR | |
| Frankfurt | 3,16 | 480 Stk | 3,20 | 480 Stk | 1714140484 16:08 | 3,16 EUR | |
| Düsseldorf | 2,82 | 2.000 Stk | 3,40 | 2.000 Stk | 1714152638 19:30 | 2,82 EUR | |
| München | 3,16 | 10.000 Stk | 3,28 | 10.000 Stk | 1714111397 08:03 | 3,30 EUR | |
| Gettex | 3,16 | 155 Stk | 3,28 | 155 Stk | 1714160647 21:44 | 3,28 EUR | |
| Quotrix Düsseldorf | 2,82 | 2.000 Stk | 3,40 | 2.000 Stk | 1714132117 13:48 | 3,40 EUR | |
| Nasdaq | 3,40 | 1.000 Stk | 3,50 | 3.400 Stk | 1714161600 22:00 | 1.757 Stk | 3,49 USD | ges. 4.849 Stk |
Börsennotierung
| Marktkapitalisierung in EUR |
|---|
| 191,4 Mio. |
| Anzahl der Aktien |
| 58,4 Mio. |
Termine
| 29.08.2024 | Quartalsmitteilung |
|---|
Grundlegende Daten zur Opthea Aktie
| Finanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| KUV | - | 52.959,00 | 9.158,00 | 4.225,50 | - | - | - |
| Ergebnis je Aktie (bereinigt) | -0,21 | -0,13 | -1,50 | -1,92 | - | - | - |
| Cashflow | -5,7 Mio. | -45,5 Mio. | -71,3 Mio. | -0,1 Mrd. | - | - | - |
| Eigenkapitalquote | 90,15 % | 97,74 % | 79,90 % | - | - | - | - |
| Verschuldungsgrad | 10,92 | 2,31 | 25,16 | - | - | - | - |
| EBIT | 59.061 | -39,3 Mio. | -96,3 Mio. | -0,1 Mrd. | - | - | - |
| Fundamentaldaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| KCV | - | -81,48 | -7,96 | -2,59 | - | - | - |
| Kurs-Gewinn-Verhältnis (KGV) | - | -81,48 | -6,11 | -2,20 | - | - | - |
| Bilanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| Umsatzerlöse | 59.061 | 68.613 | 90.683 | 108 Tsd. | - | - | - |
| Ergebnis vor Steuern | -16,8 Mio. | -50,3 Mio. | -99,1 Mio. | -0,1 Mrd. | - | - | - |
| Steuern | -5,7 Mio. | -4,9 Mio. | -6,3 Mio. | -5,9 Mio. | - | - | - |
Info Opthea Aktie
Opthea
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The companys development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.